An open-label, randomized trial of the effects of macrophage versus granulocyte colony-stimulating factor on natural killer cell activity, lymphokine activated killer cell activity, interleukin-2 production, and leukocyte count in patients after chemotherapy for ovarian cancer

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 10, 1997, Pages 698-705

  Suzuki, Mitsuaki ^a   Ohwada, Michitaka ^a   Shimizu, Yoshio ^b   Yamada, Muneo ^c   Sato, Ikuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Research Laboratory   (Japan)

Author keywords

Chemotherapy; Colony stimulating factors; Immune function; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LEUKOPROL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030664947     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80104-X     Document Type: Article

References (17)

1. Motoyoshi K, Takaku F, Mizoguchi H, et al. Purification and some properties of colony-stimulating factor from normal human urine. Blood. 1978;52:1012-1020.
2. Asim K, Beryl J, Ian ED, et al. In vivo effect of macrophage colony-stimulating factor on human monocyte function. Br J Haematol. 1991;77:25-31.
3. Hashimoto S, Yoda M, Yamada M, et al. Macrophage colony-stimulating factor induces interleukin-8 production in human monocyte. Exp Hematol. 1996;24:123-128.
4. Sakurai T, Suzu S, Yamada M, et al. Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor. Jpn J Cancer Res. 1994;85: 80-85.
5. Suzu S, Yokota H, Yamada M, et al. Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res. 1989;49:5913-5917.
6. Masaoka T, Shibata H, Ohno R, et al. Double blind test of human urinary macrophage colony-stimulating factor for allogeneic bone marrow transplantation. Br J Haematol. 1990;76:501-505.
7. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 1986;319:415-418.
8. Souza LM, Boone TC, Gabrrilove BJ, et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science. 1986;232: 61-65.
9. Lanier LL, Le AM, Phillips JH, et al. Subpopulation of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigen. J Immunol. 1983;131: 1789-1796.
10. Kimura S, Katou H, Mukai S, et al. Effects of M-CSF or GM-CSF and role of monocytes on LAK cell activity. Biotherapy. 1996;10:65-71.
11. Gillis S, Mochizuki DY, Conlon PJ, et al. Molecular characterization of interleukin 2. Immunol Rev. 1982;63:167-209.
12. Warren ML, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of IFN, TNF and colony stimulating activity. J Immunol. 1986;137:2281-2285.
13. Moore RN, Oppenhein JJ, Farrar JJ, et al. Production of lymphocyte-activating factor (IL-1) by macrophage activated with colony-stimulating factor. J Immunol. 1980;125: 1302-1305.
14. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 1989;169:1543-1555.
15. Saleh MN, Golkman SJ, Lobuglio AF, et al. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood. 1995;85:2910-2917.
16. Ohno R, Miyawaki S, Hatake K, et al. Macrophage colony-stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML). Blood. 1995;86(Suppl 1):266. Abstract.
17. Kariya Y, Taga T, Uchia A. Suppression of NK cell activity by recombinant human granulocyte colony-stimulating factor (G-CSF). Clin Immunol. 1993;25:1112-1117. In Japanese.